Claims for Patent: 6,350,885

Summary for Patent: 6,350,885

Title:	Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
Abstract:	Tricyclic heteroaromatic compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer\'s disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson\'s disease, Huntington\'s disease, prion diseases, myasthenia gravis, and Duchenne\'s muscular dystrophy.
Inventor(s):	O\'Brien; Patrick Michael (Stockbridge, MI), Picard; Joseph Armand (Canton, MI), Sliskovic; Drago Robert (Saline, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	09/719,026
Patent Claims:	1. A compound of Formula I ##STR53## wherein n is an integer of 1 or 2; X is --O--, or --S; Z is ##STR54## wherein R.sup.7 is OR.sup.8 wherein R.sup.8 is hydrogen, alkyl, --(CH.sub.2).sub.m -aryl wherein m is zero or an integer of 1 to 6, --(CH.sub.2).sub.m -heteroaryl wherein heteroaryl is a 5-6 membered heteroaromatic ring having up to 3 heteroatoms selected from N, O and S, and m is as defined above, --(CH.sub.2).sub.m -cycloalkyl having 3-7 carbon atoms in the ring wherein m is as defined above or ##STR55## wherein R.sup.9 and R.sup.9 a are either the same or different and are hydrogen, alky of 1-6 carbon atoms, aryl, arylalkyl, heteroaryl, or cycloalkyl; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are either the same or different and are hydrogen, fluorine, alkyl, alkenyl of 2-10 carbon atoms, alkynyl of 2-10 carbon atoms, arylalkenyl, heteroarylalkenyl, arylalkynyl, heteroarylalkynyl, --(CH.sub.2).sub.m -aryl wherein m is as defined above, --(CH.sub.2).sub.m -heteroaryl as defined above, --(CH.sub.2).sub.m -cycloalkyl as defined above, --(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-alkyl wherein X.sup.a is O, S, SO, SO.sub.2, or NH, and q and q.sup.1 are each zero or an integer of 1 to 6, and the sum of q+q.sup.1 is not greater than six, --(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-aryl wherein X.sup.a, q, and q.sup.1 are as defined above, --(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-heteroaryl wherein X.sup.a, q, and q.sup.1 are as defined above, or (CH.sub.2).sub.m --R.sup.10 wherein R.sup.10 is ##STR56## wherein R.sup.11 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, or cycloalkyl, ##STR57## wherein R.sup.11 is as defined above, ##STR58## wherein R.sup.11 is as defined above, ##STR59## wherein Y is nitrogen, oxygen, sulfur, or CH.sub.2 and R.sup.11 and n are as defined above and m is as defined above, OR.sup.11 wherein R.sup.11 is as defined above, ##STR60## wherein R.sup.11 and R.sup.11a are the sane or different and are as defined above for R.sup.11, --SR.sup.11 wherein R.sup.11 is as defined above, ##STR61## wherein R.sup.11 is as defined above, ##STR62## wherein R.sup.11 is as defined above ##STR63## wherein R.sup.11 is a defined above, ##STR64## wherein R.sup.11 and R.sup.11a are the same or different and are as defined above for R.sup.11, ##STR65## wherein R.sup.11 is as defined above, ##STR66## wherein R.sup.11 is as defined above, ##STR67## wherein R.sup.11 is as defined above, or ##STR68## wherein R.sup.11 and R.sup.11a are the same or different and are as defined above for R.sup.6, or ##STR69## wherein R.sup.11 and R.sup.11a are as defined above; and R.sup.5 is OH or --NHOH; with the proviso that when n is 1, Z is ##STR70## and R.sup.5 is OR.sup.12 wherein R.sup.12 is as defined above, then at least one of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is not hydrogen; and corresponding isomers thereof, or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 which is ##STR71## 3. The compound according to claim 1 which is ##STR72## 4. The compound according to claim 1 which is ##STR73## 5. The compound according to claim 1 which is ##STR74## 6. The compound according to claim 1 which is ##STR75## 7. The compound according to claim 1 which is ##STR76## 8. A compound selected from the group consisting of: 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid; N-Hydroxy-4-hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyramid e; N-Hydroxy-4-oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyramide; 4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid; 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3 -yl)-ethyl]-5-phenyl-pentanoic acid; 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl-hexanoic acid; 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl-heptanoic acid; 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl-octanoic acid; (S) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyri c acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl -pentanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl -hexanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl -heptanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl -octanoic acid; (S) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-oxo-4-(6,7,8,9-tetrahydro- dibenzofuran-3-yl)-butyric acid; (S) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-4-(6,7,8,9-tetrahy dro-dibenzofuran-3-yl)-butyric acid; (S) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-oxo-2-(6,7,8,9-tetrahydro-dib enzofuran-3-yl)-ethyl]-pentanoic acid; (S) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-hydroxyimino-4-(6,7,8,9-te trahydro-dibenzofuran-3-yl)-butyric acid; (S) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-hydroxyimino-4-(6,7,8, 9-tetrahydro-dibenzofuran-3-yl)-butyric acid; (S) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-hydroxyimino-2-(6,7,8,9-tetra hydro-dibenzofuran-3-yl)-ethyl]-pentanoic acid; (S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-diox o-imidazolidin-1-ylmethyl)-butyric acid; (S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trimethy l-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-triethyl- 2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid; (S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4 -trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; 4-Hydroxy-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid; 2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl-penta noic acid; 2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl-hexan oic acid; 2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl-hepta noic acid; 2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl-octan oic acid; 4-Hydroxy-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid; 4-Hydroxy-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; 2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trime thyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; 4-Oxo-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-butyric acid; 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-butyric acid; (S) 4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-but yric acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-5-phe nyl-pentanoic acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-6-phe nyl-hexanoic acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-7-phe nyl-heptanoic acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-8-phe nyl-octanoic acid; (S) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen- 2-yl)-butyric acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-5-phenyl-pentanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-6-phenyl-hexanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-7-phenyl-heptanoic acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-8-phenyl-octanoic acid; 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-butyric acid; 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-butyric acid; (S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid; (S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3,4,4-trime thyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid; (S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-tri methyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3, 4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (R) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyri c acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl -pentanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl -hexanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl -heptanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl -octanoic acid; (R) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-oxo-4-(6,7,8,9-tetrahydro- dibenzofuran-3-yl)-butyric acid; (R) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-4-(6,7,8,9-tetrahy dro-dibenzofuran-3-yl)-butyric acid; (R) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-oxo-2-(6,7,8,9-tetrahydro-dib enzofuran-3-yl)-ethyl]-pentanoic acid; (R) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-hydroxyimino-4-(6,7,8,9-te trahydro-dibenzofuran-3-yl)-butyric acid; (R) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-hydroxyimino-4-(6,7,8, 9-tetrahydro-dibenzofuran-3-yl)-butyric acid; (R) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-hydroxyimino-2-(6,7,8,9-tetra hydro-dibenzofuran-3-yl)-ethyl]-pentanoic acid; (R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-diox o-imidazolidin-1-ylmethyl)-butyric acid; (R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trimethy l-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl -2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid; (R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4 -trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (R) 4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-but yric acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-5-phe nyl-pentanoic acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-6-phe nyl-hexanoic acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-7-phe nyl-heptanoic acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-8-phe nyl-octanoic acid; (R) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen- 2-yl)-butyric acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-5-phenyl-pentanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-6-phenyl-hexanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-7-phenyl-heptanoic acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-8-phenyl-octanoic acid; (R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid; (R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3,4,4-7-tri methyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; (R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid; (R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-tri methyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid; (R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3, 4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier. 10. The method of inhibiting a matrix metalloproteinase comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 11. The method of inhibiting gelatinase A comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 12. The method of inhibiting stromelysin-1 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 13. The method of inhibiting collagenase-3 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 14. The method of preventing atherosclerotic plaque rupture comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 15. The method of inhibiting aortic aneurysm comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 16. The method of inhibiting heart failure comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 17. The method of preventing restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 18. The method of controlling periodontal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 19. The method of treating corneal ulceration comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 20. The method of treating burns comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 21. The method of treating decubital ulcers comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 22. The method of treatment for healing wounds comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 23. The method of treating arthritis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 24. The method of treating osteoporosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 25. The method of treating inflammation and pain comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 26. The method of treating renal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 27. The method of treating left ventricular dilation comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 28. The pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

Details for Patent 6,350,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2018-07-30